



Cite this: *Org. Biomol. Chem.*, 2017, **15**, 7977

## Correction: Stereodivergent synthesis of right- and left-handed iminoxylitol heterodimers and monomers. Study of their impact on $\beta$ -glucocerebrosidase activity

Fabien Stauffert,<sup>a</sup> Jenny Serra-Vinardell,<sup>b</sup> Marta Gómez-Grau,<sup>b</sup> Helen Michelakakis,<sup>c</sup> Irene Mavridou,<sup>c</sup> Daniel Grinberg,<sup>b</sup> Lluïsa Vilageliu,<sup>b</sup> Josefina Casas,<sup>d</sup> Anne Bodlener,<sup>\*a</sup> Antonio Delgado<sup>\*d,e</sup> and Philippe Compain<sup>\*a</sup>

DOI: 10.1039/c7ob90148h  
rsc.li/obc

Correction for 'Stereodivergent synthesis of right- and left-handed iminoxylitol heterodimers and monomers. Study of their impact on  $\beta$ -glucocerebrosidase activity' by Fabien Stauffert *et al.*, *Org. Biomol. Chem.*, 2017, **15**, 3681–3705.

The authors regret that two references were omitted from the discussion concerning the heterodimeric concept and the role of the linker length in divalent inhibitors (pages 3682–3683).<sup>1,2</sup> The additional references are given below.

In addition, since examples of divalent inhibitors based on enantiomeric iminosugar heads have been previously reported,<sup>1</sup> the word 'unprecedented' should be deleted from the contents entry. The correct entry should read: "Janus-faced iminosugars act as pharmacological chaperones for the treatment of Gaucher disease."

The Royal Society of Chemistry apologises for these errors and any consequent inconvenience to authors and readers.

## References

- 1 Exploring the divalent effect in fucosidase inhibition with stereoisomeric pyrrolidine dimers: A. Hottin, D. W. Wright, E. Moreno-Clavijo, A. J. Moreno-Vargas, G. J. Davies and J.-B. Behr, *Org. Biomol. Chem.*, 2016, **14**, 4718.
- 2 Expanding the library of divalent fucosidase inhibitors with polyamino and triazole-benzyl bridged bispyrrolidines: A. Hottin, S. Carrión-Jiménez, E. Moreno-Clavijo, A. J. Moreno-Vargas, A. T. Carmona, I. Robina and J.-B. Behr, *Org. Biomol. Chem.*, 2016, **14**, 3212.

<sup>a</sup>Laboratoire de Synthèse Organique et Molécules Bioactives (SYBIO), Université de Strasbourg/CNRS (UMR 7509), Ecole Européenne de Chimie, Polymères et Matériaux (ECPM), 25 rue Becquerel, 67087 Strasbourg, France. E-mail: philippe.compain@unistra.fr, annebod@unistra.fr

<sup>b</sup>Departament de Genètica, Microbiologia i Estadística, Universitat de Barcelona (UB), IBUB, IRSJD, CIBER de Enfermedades Raras (CIBERER), Av. Diagonal 645, E-08028 Barcelona, Spain

<sup>c</sup>Department of Enzymology and Cellular Function, Institute of Child Health, Athens, 11527, Greece

<sup>d</sup>Research Unit on BioActive Molecules (RUBAM), Departament de Química Biomèdica, Institut de Química Avançada de Catalunya (IQAC-CSIC), Jordi Girona 18, 08034 Barcelona, Spain. E-mail: delgado@rubam.net

<sup>e</sup>Unit of Pharmaceutical Chemistry (Associated Unit to CSIC), Department of Pharmacology, Toxicology and Medicinal Chemistry, Faculty of Pharmacy, University of Barcelona (UB), Avda. Joan XXIII s/n, E-08028 Barcelona, Spain

